-
Mashup Score: 15FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC - 19 hour(s) ago
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC - 21 day(s) ago
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC #lcsm #medtwitter #oncology https://t.co/ge8TFR173o
-
-
Mashup Score: 3FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC - 23 day(s) ago
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC #lcsm #medtwitter #oncology https://t.co/ge8TFR173o
-
-
Mashup Score: 3FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC - 1 month(s) ago
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC #lcsm #medtwitter #oncology https://t.co/ge8TFR173o
-
-
Mashup Score: 2Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation - 1 month(s) ago
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation #lcsm #medtwitter #oncology https://t.co/Vc7WQl1qXD
-
-
Mashup Score: 2Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation - 1 month(s) ago
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation #lcsm #medtwitter #oncology https://t.co/Vc7WQl1qXD
-
-
Mashup Score: 0Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation - 2 month(s) ago
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation #lcsm #medtwitter #oncology https://t.co/Vc7WQl1qXD
-
-
Mashup Score: 5Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC - 3 month(s) ago
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC @ipreeshagul @MSKCancercenter #lcsm #MedTwitter #oncology https://t.co/lT9a0ccmlR
-
-
Mashup Score: 5Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC - 3 month(s) ago
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC @ipreeshagul @MSKCancercenter #lcsm #MedTwitter #oncology https://t.co/lT9a0ccmlR
-
-
Mashup Score: 5Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC - 3 month(s) ago
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC @ipreeshagul @MSKCancercenter #lcsm #MedTwitter #oncology https://t.co/lT9a0ccmlR
-
Sacituzumab govitecan has received a breakthrough therapy designation by the @US_FDA for patients with extensive-stage SCLC in the second line. #LCSM #MedTwitter #Oncology Read here: https://t.co/4kewtUWn2T